Private Equity Second Bite: Ophthalmology Equity Rollover
An ophthalmology equity rollover is one of the most important and least understood parts of a private equity transaction. Instead of receiving the entire purchase price in cash at closing, selling physicians reinvest part of their proceeds into equity in the buyer’s platform. If the platform is later sold at a higher value, that retained equity may produce a second payout, often called the “second bite of the apple.”
For ophthalmologists weighing an offer, the rollover can be a meaningful share of total consideration, which is why it deserves as much attention as the headline price. Deal terms vary widely, and nothing here is legal, tax or investment advice. Sellers should work with healthcare counsel, tax advisors and accountants before agreeing to any structure.
How an Ophthalmology Equity Rollover Works
In a typical private equity transaction, the buyer acquires the practice’s business operations and assets, and the selling physicians receive consideration in a few forms:
- Cash at closing: the portion paid up front
- Rollover equity: an ownership interest in the buyer’s holding company or platform
- Contingent payments: in some deals, earnouts tied to future performance, which may be limited by lenders or financing terms and are not certain to be paid
Physicians also usually sign employment agreements, and their future compensation may be reduced compared with what they earned as owners. The difference in compensation is part of what supports the purchase price.
The rollover piece is not cash. Its value depends on how the platform performs and the price it achieves at a future sale, which is not certain to occur on any particular schedule or at any particular value.
Why Buyers Want Physicians to Roll Equity
Private equity groups often ask sellers to roll over part of their proceeds for several reasons:
- It aligns the physicians’ interests with the growth of the platform
- It reduces the cash the buyer needs at closing
- It signals that the sellers believe in the combined business
- It encourages surgeons to stay productive after the sale
From the seller’s side, the rollover offers potential upside but also concentrates personal wealth in a single, illiquid investment.
Key Terms to Review in a Rollover
Two offers with the same headline price can produce very different outcomes depending on the rollover terms. Sellers should understand:
Which Entity You Are Investing In
Rollover equity may be issued at the top holding company or at a lower level. The entity affects what share of future sale proceeds physicians may receive and how much debt sits ahead of their equity.
Class of Equity and Preferences
Investors sometimes hold preferred equity that is paid back before other equity holders. Sellers should understand where their units sit in the payout order and whether any preferred returns must be paid first.
Valuation of the Rolled Equity
Sellers should ask how their rollover units are valued at closing and whether that value is consistent with the price the investor is paying for its own equity.
Platform Debt
Platforms often use significant borrowing to fund acquisitions. Debt is repaid before equity holders at a future sale, so the amount of leverage can affect the value of the second bite.
Liquidity and Transfer Restrictions
Rollover equity is generally illiquid. Agreements may limit transfers, require consent for sales and include drag-along and tag-along rights that govern what happens when the investor sells.
Employment-Linked Provisions
Some agreements allow the platform to repurchase a physician’s equity if employment ends, sometimes at a reduced price. Sellers should understand how departure, disability, retirement or termination affects their units.
Tax Treatment of an Ophthalmology Equity Rollover
Depending on how the transaction is structured, part of the rollover may be eligible for tax deferral, while the cash portion is generally taxable at closing. Structure, entity type and price allocation can all affect the outcome. Sellers should rely on tax advisors for this analysis. Our article on taxes on selling an ophthalmology practice explains why price allocation matters.
Evaluating the Second Bite Realistically
Rollover equity is often presented with projections of future value. Projections are estimates, not promises. When evaluating an ophthalmology equity rollover, sellers may want to consider:
- The platform’s acquisition strategy and integration track record
- How reimbursement changes, including Medicare payment policy, could affect earnings
- How much debt the platform carries now and plans to add
- Who decides when and how the platform will be sold
- What happens if the platform is sold for less than expected
- How much of the seller’s net worth will be tied to one investment
Many sellers compare the after-tax cash at closing, the potential range of rollover outcomes and post-sale compensation against the alternative of staying independent.
Comparing Private Equity With Other Paths
A private equity sale is not the only option for ophthalmologists planning their future. Alternatives may include selling to an associate or partner, merging with another independent group or planning a gradual internal transition. Each path has different financial, cultural and tax outcomes.
Our related articles on selling an ophthalmology practice to private equity and an ophthalmology practice merger as an alternative to private equity walk through those choices. Before evaluating any offer, it also helps to understand how buyers view your practice; our guide on how to value an ophthalmology practice is a good starting point.
Final Thoughts
The second bite can be a meaningful part of a private equity transaction, but it is also the least certain part of the consideration. Understanding the entity, equity class, debt load, restrictions and tax treatment of rollover equity can help ophthalmologists compare offers on a realistic basis and decide whether a sale fits their goals.
US Medical Funding helps physicians evaluate their options when planning a sale or succession. Learn more about our advisory and consulting services and our ophthalmology practice financing solutions.
